Indication
NY-ESO-1 Positive
1 clinical trial
2 products
4 drugs
Clinical trial
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced MalignanciesStatus: Terminated, Estimated PCD: 2023-10-19
Drug
interleukin-2Product
BusulfanProduct
Cellular TherapyDrug
FilgrastimDrug
fludarabineDrug
Plerixafor